Whitehawk Therapeutics (WHWK) Profit After Tax (2010 - 2026)

Whitehawk Therapeutics (WHWK) has reported Profit After Tax for 17 consecutive years, with -$22.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 130.59% year-over-year to -$22.3 million; the TTM figure through Mar 2026 stood at -$116.0 million (down 519.61% YoY), while the FY2025 annual figure was -$20.5 million, up 67.83% from the prior year.
• Profit After Tax improved to -$22.3 million in Q1 2026 per WHWK's latest filing, from -$23.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $73.0 million in Q1 2025 and bottomed at -$52.6 million in Q2 2025.
• Historically, Profit After Tax has averaged -$13.7 million across 5 years, with a median of -$16.4 million in 2023.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 1089.39% — and 2025, when it jumped 499.15%.
• Whitehawk Therapeutics' Profit After Tax stood at -$13.9 million in 2022, then dropped by 17.65% to -$16.4 million in 2023, then fell by 11.82% to -$18.3 million in 2024, then dropped by 27.14% to -$23.3 million in 2025, then climbed by 4.04% to -$22.3 million in 2026.
• Business Quant data shows WHWK's Profit After Tax at -$22.3 million in Q1 2026, -$23.3 million in Q4 2025, and -$17.7 million in Q3 2025.